Jump to content


Biomarker for Diffuse Scleroderma skin has been discovered!


Photo

Rituximab therapy in patients with refractory dermatomyositis (DM) or polymyositis (PM): differential effects in a real-life population.

dermatomyosis polymyositis

  • Please log in to reply
No replies to this topic

#1 Joelf

Joelf

    Star Ruby Member

  • ISN Root Admin
  • PipPipPipPipPipPipPipPipPipPipPipPipPip
  • 4,610 posts
  • Location:West Sussex

Posted 14 July 2014 - 12:20 PM

Rituximab therapy in patients with refractory dermatomyositis (DM) or polymyositis (PM): differential effects in a real-life population.

 

Objective improvement was seen in the majority of patients with regard to creatine phosphokinase (CPK) and lung function tests, and glucocorticoids could be reduced. PubMed, Rheumatology (Oxford). 2014 Apr 4. (Also see: Dermatomyositis and Polymyositis Treatments)

 

This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.


Jo Frowde
ISN Assistant Webmaster

SD World Webmaster
ISN Sclero Forums Manager
ISN News Manager

ISN Hotline Support Specialist
ISN Chat Host
International Scleroderma Network (ISN)